Logo

Galapagos Signs Two-Year, $1.7M Research Deal with CF Foundation

Apr 14, 2005

NEW YORK, April 14 (GenomeWeb News) - Galapagos has signed a two-year, €1.3 million ($1.7 million) agreement with Cystic Fibrosis Foundation Therapeutics, the drug discovery and development affiliate of the Cystic Fibrosis Foundation, the company said yesterday.

 

Galadeno, Galapagos' Leiden, Netherlands-based services unit, will apply the company's siRNA and cDNA collections to discover and validate novel drug targets for potential new cystic fibrosis therapies. Galapagos will have the option to further develop targets, the company said.

 

Breaking News
The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.